AMCARE develops regenerative therapies which aim to circumvent some of the limitations of current treatments for myocardial infarction patients. Our rationale is to use biomaterials to deliver cells or growth factors to the heart.
A number of different adult cardiac stem cells are currently utilized in clinical trials. While these cells have shown little to no ability to differentiate into functional mature cardiomyocytes, their ability to improve cardiac function has been demonstrated in many studies. One reason for the lack of regeneration by adult stem cell therapies may be that many of the cells are ejected by the powerful beat of the heart after injection. A potential solution to this problem will be developed in the EU FP7 project Advanced Materials for Cardiac Regeneration (AMCARE) where smart biomaterials and advanced drug delivery methods are coupled with therapeutics to create minimally-invasive surgical approaches to improve the delivery of adult cardiac stem cells to the ischemic heart.